睿昂基因(688217) - 2021 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2021 was ¥72,937,626.80, representing a year-on-year increase of 5.20%[5] - The net profit attributable to shareholders for the same period was ¥17,807,204.65, an increase of 21.64% compared to the previous year[5] - Total operating revenue for the first three quarters of 2021 reached ¥208,957,521.99, a slight increase of 0.8% compared to ¥205,308,678.16 in the same period of 2020[22] - Operating profit for Q3 2021 was ¥39,777,053.58, up 28.1% from ¥31,085,789.13 in Q3 2020[23] - Net profit attributable to shareholders of the parent company for Q3 2021 was ¥42,736,350.75, an increase of 50.7% compared to ¥28,363,921.79 in Q3 2020[24] Research and Development - Research and development expenses totaled ¥21,157,140.03 in Q3 2021, accounting for 29.01% of operating revenue, which is an increase of 8.33 percentage points year-on-year[6] - The company has ongoing research and development efforts, focusing on new product innovations and technology advancements, although specific figures were not disclosed[16] - Research and development expenses for Q3 2021 totaled ¥53,941,908.56, slightly higher than ¥51,135,165.93 in Q3 2020, indicating continued investment in innovation[23] Assets and Liabilities - Total assets increased by 33.27% year-on-year, reaching ¥948,523,861.05 by the end of the reporting period[6] - Current assets totaled RMB 587,786,045.86, up from RMB 389,105,049.39, indicating a growth of about 50.9% year-over-year[17] - Total liabilities were reported at RMB 37,352,520.30, slightly down from RMB 37,523,882.79, indicating a decrease of about 0.5%[18] - Total liabilities increased to ¥52,773,196.26 in Q3 2021 from ¥49,924,013.97 in Q3 2020, reflecting a growth of 5.7%[23] - The total equity attributable to shareholders increased by 36.73% year-on-year, amounting to ¥884,218,721.21 by the end of the reporting period[6] - The company's total equity reached ¥895,750,664.79 in Q3 2021, up from ¥661,788,713.09 in Q3 2020, marking a significant increase of 35.3%[23] Cash Flow - The company reported a net cash flow from operating activities of ¥45,474,389.59 for the year-to-date period, which reflects a decrease of 8.40% year-on-year[6] - The company reported a net cash flow from operating activities of ¥45,474,389.59 for the first three quarters of 2021, down 8.8% from ¥49,646,134.13 in the same period of 2020[27] - Cash inflow from operating activities totaled ¥244,486,040.42 for the first three quarters of 2021, compared to ¥222,168,215.10 in the same period of 2020, an increase of 10%[27] - The net cash flow from investing activities was -228,225,662.57 RMB, compared to -22,527,416.84 RMB in the previous period[28] - The net cash flow from financing activities was 195,208,388.95 RMB, a significant increase from -10,848,100.00 RMB in the prior period[28] Government Support and Market Strategy - The company received government subsidies amounting to ¥6,585,520.84 during the reporting period, which contributed positively to the financial results[8] - The company is exploring market expansion opportunities, although detailed strategies and targets were not provided in the report[16] - There were no significant mergers or acquisitions reported during the quarter, with a focus on organic growth strategies[16] Earnings Per Share - The basic earnings per share for the year-to-date period was ¥0.32, reflecting a decrease of 8.57% compared to the same period last year[6] - The basic earnings per share for Q3 2021 was ¥0.89, compared to ¥0.68 in Q3 2020, representing a growth of 30.9%[24]